Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2Recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Dermatologic 1

Conditions

Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 117Carboplatin 47Nivolumab 46Paclitaxel 34Cyclophosphamide 34Cisplatin 33Gemcitabine 30atezolizumab 27Specimen Handling 26Magnetic Resonance Spectroscopy 25venetoclax 24Docetaxel 24fludarabine 23Pemetrexed 23Biopsy 22Bevacizumab 22Radiotherapy 21Ipilimumab 21Azacitidine 20Dexamethasone 19Radiosurgery 18durvalumab 17Fluorouracil 17Cetuximab 16Trastuzumab 15fludarabine phosphate 14Leucovorin 14Cytarabine 14tislelizumab 13Lenalidomide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Toll-Like Receptor 1 × 1 year × Clear all
NCT03645928 2026-05-15

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Iovance Biotherapeutics, Inc.

Phase 2 Terminated
225 enrolled
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT03108495 2025-09-17

Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma

Iovance Biotherapeutics, Inc.

Phase 2 Terminated
210 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡